Wangbi capsule for active rheumatoid arthritis:a multicenter,randomized,double-blind,parallel-controlled study

Objective To evaluate the efficacy and safety of Wangbi Capsule(WBC)in the treatment of active rheumatoid arthritis(RA).Methods Totally 101 patients in line with inclusion criteria from 114 patients with active RA were assigned to the treatment group(52 cases)and the control group(49 cases)by using block randomization method,which was stratified by center with a selected segment length of 2 and the PROC PLAN procedure statement in SAS9.4 Software used to give the number of seeds.Patients in the treatment group took WBC+methotrexate(MTX),while those in the control group took WBC placebo+MTX.The treatment course lasted for 12 weeks.By comparing the 28 joint disease activity scores(DAS28-ESR)based1onerythrocyte sedimentation rate(ESR),28 joint disease activity scores(DAS28-CRP)based onC-reactive protein(CRP),DAS28-ESR remission rate,DAS28-CRP remission rate,ESR,CRP,rheumatoid factor(RF),and anti-cyclic citrulline antibody(ACPA)before and after treatment,patient visual analogue score(VAS),physician VAS score,joint pain count,joint swelling count.